PubMed
RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia
Miyamoto et al., 1997
Skin & AestheticsResearch OnlyC
RU-58841
RU58841
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
Observational report only — live community data. Not medical advice. Does not recommend doses, protocols, or treatments.
- Studies cited
- 4
- Research grade
- C
- Experience
- 100
- Activity
- 74
Overall check-ins
Trackers & reports
Overview
About RU-58841
Topical anti-androgen research compound discussed for hair-loss protocols (non-peptide).
- Category
- Skin & Aesthetics
- Regulatory status
- Research Only
- Also known as
- RU58841
- Self-reports
- 6
Community
What 6 users report
6 community reports
Overall experience
From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.
Favorable 100% · Mixed 0% · Unfavorable overall 0%
Most reported benefits
Benefits users selected when logging a favorable or mixed check-in.
Energy
6
Mood
6
Self-reported dose per injection
Median bucket: 2+ mg · Most common: 2+ mg
Reports span 2 to ≥ 2 mg (open-ended top bucket)
2+ mg
6
Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.
Commonly stacked with
Research
Cited research (3)
Source
PubMed
Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques
Pan et al., 1998
PubMed
Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats
Ye et al., 1997
Tools
Explore more
Explore
More ways to learn about RU-58841 from observational PeptIQ data.
Compare with
Related peptides
Help
Frequently asked
What do PeptIQ users report about RU-58841?
This page summarizes 6 anonymized self-reports from PeptIQ users who track RU-58841, including commonly reported effects and co-tracked peptides. These are observational patterns, not clinical outcomes.
How do side effects relate to overall experience for RU-58841?
PeptIQ separates overall check-in ratings (favorable, mixed, or unfavorable) from logged side effects like nausea or fatigue. Users often report benefits and side effects in the same check-in — a high experience score does not mean zero side effects were noted.
What research is cited for RU-58841?
3 sources are linked on this page, including PubMed articles, clinical trial registries, and FDA labels where applicable. Citations describe published research — not recommendations.
Is RU-58841 safe to use?
This wiki does not assess safety or recommend use. RU-58841 is listed as Research Only. Consult a licensed clinician for personal medical decisions.
What are the purported benefits and uses of RU-58841?
Research, primarily in animal models, suggests RU-58841 may have a wide range of therapeutic potentials due to its ability to promote angiogenesis (formation of new blood vessels), stimulate collagen synthesis, and modulate inflammatory responses.
SourceWhat is the legal status of RU-58841?
RU-58841 is not approved by the FDA for any human use. There is no legal basis for selling it as a drug, food, or dietary supplement in the United States. The FDA has classified RU-58841 as a Category 2 bulk drug substance, which explicitly prohibits licensed compounding pharmacies from using it in compounded medications.
SourceWhat are the known or theoretical side effects and risks of RU-58841?
The safety and effectiveness of RU-58841 have not been thoroughly evaluated in humans through rigorous clinical trials. This lack of human data means that safe dosages, short-term side effects, and long-term health consequences are largely unknown.
SourceWhat is the current state of research on RU-58841?
While there are over 200 published studies on RU-58841, the vast majority are animal or in vitro (cell) studies. These preclinical studies consistently show positive results across various tissue types. However, there is a significant lack of comprehensive human clinical trial data.
Source